This identification that the phase of disease matters is so important—thank you for sharing the learnings. I wonder if incorporating this principle into Alzheimer’s trials would have solved some of the failures there. What if GLP-1s were used in the compensatory window before microglial burnout? What if amyloid-targeted agents were used before it was measurable and the clearance pathway overwhelmed?
A very interesting piece; there is so much potential insight to be garnered regarding identifying the underlying causes of disease heterogeneity. Away from Neurodegeneration, in epilepsy and psychiatry (depression) roughly one third of patients do not respond to current treatments. Would be very interesting to see if the team could help unlock the biological underpinnings in these examples.
This identification that the phase of disease matters is so important—thank you for sharing the learnings. I wonder if incorporating this principle into Alzheimer’s trials would have solved some of the failures there. What if GLP-1s were used in the compensatory window before microglial burnout? What if amyloid-targeted agents were used before it was measurable and the clearance pathway overwhelmed?
A very interesting piece; there is so much potential insight to be garnered regarding identifying the underlying causes of disease heterogeneity. Away from Neurodegeneration, in epilepsy and psychiatry (depression) roughly one third of patients do not respond to current treatments. Would be very interesting to see if the team could help unlock the biological underpinnings in these examples.
Great analysis Alice.
I am looking forward to hearing more of this story and what direction CONVERGE 2 will take us.
I am always ready to drug a new target!